Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
14 pending office actions • 12 clients • 13 examiners • 12 art units • 0 of 14 (0%) have an AI response strategy ready
Culhane Meadows PLLC focuses on Biotechnology & Pharmaceuticals. The profile shows 14 pending office actions and 657 career applications, indicating an active but defined current workload supported by a substantial historical record.
The resolved allowance rate is 90.06%, and the average is 3.77 office actions per allowance. Resolved matters frequently reach allowance, although the average indicates that several examination exchanges may be required. Practitioners should use the favorable outcome measure for portfolio context while reviewing the scientific disclosure, claim strategy, and cited art in each pending matter.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (29%) |
| §102 only | 1 (7%) |
| §112 only | 2 (14%) |
| Double-patenting only | 1 (7%) |
| Multi-statute (no §101) | 6 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 2 | 71.2% | +0.3% |
| GURTOWSKI, RICHARD C | 1 | 72.3% | +37.8% |
| SONG, JIANFENG | 1 | 56.4% | +33.0% |
| GZYBOWSKI, MICHAEL STANLEY | 1 | 67.6% | +52.2% |
| REDDY, KARUNA P | 1 | 42.6% | +10.4% |
| PALENIK, JEFFREY T | 1 | 53.5% | +27.0% |
| PATERSON, BRIGITTE A | 1 | 76.7% | +22.4% |
| PURDY, KYLE A | 1 | 41.0% | +35.7% |
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| STOCKTON, LAURA LYNNE | 1 | 75.3% | +33.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17554511 | INTEGRATED ELECTRONICS ON THE ALUMINUM NITRIDE PLATFORM | SHEKER, RHYS PONIENTE | 22d |
| 18502783 | PROTONATED pH RESPONSIVE POLYMER ENCAPSULATION OF BISPECIFIC ANTIBODIES AND CYTOKINES | SONG, JIANFENG | — |
| 18551012 | VIRAL FILTER AND METHOD OF VIRAL FILTRATION | GZYBOWSKI, MICHAEL STANLEY | — |
| 18280649 | CROSSLINKED POLY (ALLYLAMINE) POLYMER PHARMACEUTICAL COMPOSITIONS | REDDY, KARUNA P | — |
| 18277519 | Integrated Quantum Computing with Epitaxial Materials | PATERSON, BRIGITTE A | — |
| 18008271 | COMPOSITIONS | PURDY, KYLE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17784243 | LIQUID PHARMACEUTICAL COMPOSITION COMPRISING CYTISINE | SOROUSH, LAYLA | 9d |
| 17773216 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | STOCKTON, LAURA LYNNE | 77d |
| 18782221 | AUTOMATED FLUID HANDLING SYSTEM | GURTOWSKI, RICHARD C | — |
| 18502783 | PROTONATED pH RESPONSIVE POLYMER ENCAPSULATION OF BISPECIFIC ANTIBODIES AND CYTOKINES | SONG, JIANFENG | — |
| 18551012 | VIRAL FILTER AND METHOD OF VIRAL FILTRATION | GZYBOWSKI, MICHAEL STANLEY | — |
| 18280649 | CROSSLINKED POLY (ALLYLAMINE) POLYMER PHARMACEUTICAL COMPOSITIONS | REDDY, KARUNA P | — |
| 18238665 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | PALENIK, JEFFREY T | — |
| 18277519 | Integrated Quantum Computing with Epitaxial Materials | PATERSON, BRIGITTE A | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1618 | 2 |
| 1773 | 1 |
| 1613 | 1 |
| 1798 | 1 |
| 1764 | 1 |
| 1615 | 1 |
| 2896 | 1 |
| 1611 | 1 |
| 1622 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18797649 | COMPOSITIONS, KITS, AND METHODS TO INDUCE ACQUIRED CYTORESISTANCE USING STRESS PROTEIN INDUCERS | Fred Hutchinson Cancer Research Center | YOO, SUN JAE | 1621 | DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18782221 | AUTOMATED FLUID HANDLING SYSTEM | CYTIVA SWEDEN AB | GURTOWSKI, RICHARD C | 1773 | §112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18428728 | Novel Stannic Protoporfin Compositions, Methods of Making, and Uses Thereof | Renibus Therapeutics, Inc. | YOO, SUN JAE | 1621 | §103 | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18502783 | PROTONATED pH RESPONSIVE POLYMER ENCAPSULATION OF BISPECIFIC ANTIBODIES AND CYTOKINES | Onconano Medicine, Inc. | SONG, JIANFENG | 1613 | §103§112Other | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18551012 | VIRAL FILTER AND METHOD OF VIRAL FILTRATION | Global Life Sciences Solutions Operations UK Ltd. | GZYBOWSKI, MICHAEL STANLEY | 1798 | §103§112 | Final Rejection | — | Pending | Sep 18, 2023 |
| 18280649 | CROSSLINKED POLY (ALLYLAMINE) POLYMER PHARMACEUTICAL COMPOSITIONS | Renosis, Inc. | REDDY, KARUNA P | 1764 | §103§112 | Final Rejection | — | Pending | Sep 06, 2023 |
| 18238665 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | Renosis, Inc. | PALENIK, JEFFREY T | 1615 | §103Other | Final Rejection | — | Pending | Aug 28, 2023 |
| 18277519 | Integrated Quantum Computing with Epitaxial Materials | Cornell University | PATERSON, BRIGITTE A | 2896 | §102§112 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18008271 | COMPOSITIONS | Jvs Products Limited | PURDY, KYLE A | 1611 | §103§112 | Non-Final OA | — | Pending | Dec 05, 2022 |
| 17784243 | LIQUID PHARMACEUTICAL COMPOSITION COMPRISING CYTISINE | Adamed Pharma S.A. | SOROUSH, LAYLA | 1622 | §103 | Non-Final OA | 9d | Pending | Aug 02, 2022 |
| 17773216 | COMBINATION OF A CXCR7 ANTAGONIST WITH AN S1P1 RECEPTOR MODULATOR | Idorsia Pharmaceuticals Ltd. | STOCKTON, LAURA LYNNE | 1626 | §112 | Final Rejection | 77d | Pending | Aug 02, 2022 |
| 17756190 | PH RESPONSIVE COMPOSITIONS, FORMULATIONS, AND METHODS OF IMAGING A TUMOR | Onconano Medicine, Inc. | WESTERBERG, NISSA M | 1618 | §103Other | Final Rejection | — | Pending | May 18, 2022 |
| 17755671 | pH Responsive Block Copolymers Compositions, Micelles, and Methods of Use | Onconano Medicine, Inc. | ROGERS, JAMES WILLIAM | 1618 | §102Other | Final Rejection | 79d overdue | Pending | May 04, 2022 |
| 17554511 | INTEGRATED ELECTRONICS ON THE ALUMINUM NITRIDE PLATFORM | Cornell University | SHEKER, RHYS PONIENTE | 2813 | §103§112 | Final Rejection | 22d | Pending | Dec 17, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial90.1% of resolved applications prosecuted by Culhane Meadows, PLLC were allowed, across 657 applications in USPTO records.
3.77 office actions per allowed application on average.
14 pending office actions as of October 2026, for 12 clients, before 13 examiners in 12 art units.
